Posts filtered by tags: Agen[x]


 

Agenus Inc (AGEN) Q4 2018 Earnings Conference Call Transcript

AGEN earnings call for the period ending December 31, 2018.
Tags: Science, Agen, Agenus Inc AGEN


Pierce Phillips: Worcester lock to move to French Top 14 club Agen

Worcester's former Jersey lock forward Pierce Phillips is to join French Top 14 club Agen this summer.
Tags: Rugby, Worcester, Jersey, Agen, Pierce Phillips


Quins reach last eight with win in Agen

Harlequins qualify for the quarter-finals of the European Challenge Cup with a bonus-point victory at French side Agen.
Tags: Rugby, Harlequins, Agen, Quins


European Challenge Cup: Agen v Harlequins

Team news as Agen host Harlequins in Friday's European Challenge Cup fixture at Stade Armandie (18:45 GMT).
Tags: Rugby, Harlequins, Agen, Stade Armandie


Gilead Sciences Commits $150M to Agenus in Cancer Drug R&D Pact

For the second time this week, Gilead Sciences has partnered with a Boston-area biotech, this time with a deal that covers up to five experimental cancer immunotherapies being developed by Agenus.Under the deal terms, Foster City, CA-based Gilead (NASDAQ: GILD) will pay Agenus (NASDAQ: AGEN) $120 million cash up front and make a $30 million equity investment in the company. Depending on the progress of the drugs, Gilead could pay its Lexington, MA, partner up to $1.7 billion more in fees and mi...
Tags: Deals, Boston, Cancer, Hiv, San Francisco, Trends, Fda, Biotech, Life Sciences, Clinical Trials, Agen, Gilead Sciences, Gilead, Hepatitis C, Kite Pharma, Lexington MA


European Rugby Challenge Cup: Harlequins power to win over Agen

Harlequins score eight tries as they open their European Challenge Cup campaign with a dominant victory over Agen.
Tags: Rugby, Harlequins, Agen


European Rugby Challenge Cup: Harlequins v Agen

Team news as Harlequins host Agen in Saturday's European Rugby Challenge Cup fixture at Twickenham Stoop (15:00 BST).
Tags: Rugby, Harlequins, Agen


Gloucester beat Agen to seal Challenge Cup quarter-final spot

Gloucester secure a European Challenge Cup quarter-final place, scoring six tries in their Pool Three win over Agen.
Tags: Rugby, Gloucester, Agen


Gloucester ease to Challenge Cup win at Agen

Gloucester close in on a European Challenge Cup quarter-final place, scoring six tries in their Pool Three win over Agen.
Tags: News, Gloucester, Agen


Back rower Moriarty returns to boost injury-hit Wales

Wales receive a Six Nations boost with Ross Moriarty returning after back problems for Gloucester at Agen on Friday.
Tags: Wales, Rugby, Gloucester, Moriarty, Agen, Ross Moriarty


Ross Moriarty: Flanker boosts Wales with Gloucester return

Wales receive a Six Nations boost with Ross Moriarty returning after back problems for Gloucester at Agen on Friday.
Tags: Wales, Sport, Gloucester, Agen, Ross Moriarty


Ross Moriarty: Flanker boots Wales with Gloucester return

Wales receive a Six Nations boost with Ross Moriarty returning after back problems for Gloucester at Agen on Friday, 12 January.
Tags: News, Wales, Gloucester, Agen, Ross Moriarty


Opeti Fonua: Newcastle Falcons back-row rejoins Agen

Newcastle Falcons allow back-row Opeti Fonua to rejoin French Top 14 side Agen with immediate effect.
Tags: Rugby, Agen, Newcastle Falcons, Opeti Fonua


Why Agenus Inc. Stock Slumped Today

Shares of the cancer immunotherapy and vaccine company Agenus (NASDAQ: AGEN) fell by as much as 16.7% on nearly five times the average volume today, before ultimately ending the day down by only 5.1%. This sizable move lower was triggered by a $250 million mixed shelf offering that the company plans to use for general corporate purposes.According to the accompanying prospectus, general corporate purposes may include "working capital, capital expenditures, repayment and refinancing of debt, res...
Tags: Finance, Health Care, Agen, Getty Images Continue, 10% Promise, George Budwell, 30d10af8-b511-11e7-ba3d-0050569d32b9, Agenus Inc Stock Slumped Today


Gloucester power to nine-try victory over Agen

Gloucester score nine tries as they ease to a bonus-point victory over French side Agen in the European Challenge Cup.
Tags: Sport, Gloucester, Agen


Nine-try Gloucester power to victory over Agen

Gloucester score nine tries as they ease to a bonus-point victory over French side Agen in the European Challenge Cup.
Tags: Rugby, Gloucester, Agen


European Challenge Cup: Gloucester v Agen

Team news as Gloucester host Agen in Thursday's Challenge Cup Pool 3 fixture at Kingsholm Stadium (19:45 BST).
Tags: Rugby, Gloucester, Agen, Kingsholm Stadium


3 Top Biotech Stocks Under $5

The biotech field is littered with stocks under $5 that probably won't walk away from the crash landings that made them look so cheap. You'll be glad to know that sifting through the wreckage to find hidden gems is one daunting task that you don't need to slog through.I recently noticed a few top biotech stocks you can buy for about the same price as an iced cappuccino. Geron Corporation (NASDAQ: GERN) , Rigel Pharmaceuticals Inc. (NASDAQ: RIGL) , and Agenus Inc. (NASDAQ: AGEN) don't have an...
Tags: Finance, Fda, Health Care, Agen, GSK, Agenus Inc, Getty Images Continue, Cory Renauer, JNJ, GERN, INCY, Geron Corporation NASDAQ, RIGL, 3b1e60fa-834d-11e7-b6c7-0050569d32b9, GERN Rigel Pharmaceuticals Inc NASDAQ


3 Beaten-Up Biotech Stocks: Are They Bargains?

The iShares Nasdaq Biotechnology Index has tacked on a healthy gain of around 15% so far this year, without any help from Celldex Therapeutics, Inc. (NASDAQ: CLDX) , Agenus Inc. (NASDAQ: AGEN) , or Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) . All three of these relatively small biotechs have slipped by double-digit percentages in 2017.Is the pessimism justified, or has the market underestimated the potential value drivers within these companies' drug development pipelines? Let's take a co...
Tags: Finance, Health Care, Agen, GSK, CLDX, VRX, AZN, Getty Images Continue, Progenics Pharmaceuticals Inc, Cory Renauer, BMY, INCY, Celldex Therapeutics Inc NASDAQ, PGNX, A3e72b76-7e98-11e7-b273-0050569d32b9


Here's Why Agenus Inc. Stock Slipped 13.6% in July

Shares of Agenus Inc. (NASDAQ: AGEN) , a clinical-stage immuno-oncology company, fell 13.6% in July according to data from S&P Global Market Intelligence. Investors viewed a clinical-trial failure reported by AstraZeneca as a harbinger of sorrow for similar candidates in its own pipeline.Aside from an adjuvant featured in GlaxoSmithKline's shingles-vaccine candidate, Agenus Inc.'s future hinges on success for new drug candidates that inhibit a cancer cell's ability to exploit the CTLA-4 and PD-...
Tags: Finance, Astrazeneca, Health Care, GlaxoSmithKline, Agen, Agenus Inc, CTLA, 10% Promise, Cory Renauer, Agenus Inc NASDAQ, 92a7eef6-7937-11e7-aeda-0050569d4be0


Did the Checkpoint Inhibitor Bubble Just Burst?

Shares of Agenus (NASDAQ: AGEN) , a small-cap cancer immunotherapy company, were down by almost 16% at 1:20 p.m. Thursday as a result of AstraZeneca's (NYSE: AZN) Mystic trial missing its primary endpoint for progression-free survival in non-small cell lung cancer (NSCLC). Shares of Bristol-Myers Squibb's (NYSE: BMY) , which is pursuing a similar combination therapy for front-line NSCLC, also fell by as much as 6.8% in early morning trading, and were still off by 3.5% at 1:20 p.m. Image Sou...
Tags: Finance, Astrazeneca, Health Care, Bristol, Agen, Bristol Myers Squibb, NSCLC, MRK, AZN, George Budwell, BMY, 8412167e-72d3-11e7-aeda-0050569d4be0, Agenus AstraZeneca


3 Stocks That Are Ridiculously Cheap Right Now

When a stock goes on sale, and the stock market offers you the chance to buy it for less than it's worth, that's what we investors call a "value stock." But what do you call a stock that's selling for a lot less than it's worth?Is it ridiculous to even ask that question in a market where everything seems expensive? Maybe, maybe not. Those of us who've been around the block a few times, though, have seen the stock market misprice great businesses again and again over the years and even in markets...
Tags: Finance, Agen, HP Inc, Baidu Inc, BIDU, HPE, GOOGL, HPQ, Technology and Telecom, George Budwell, 4e848af4-68bb-11e7-a03d-0050569d4be0, Rich Smith Leo Sun


Better Buy: Agenus Inc. vs. Kite Pharma

Cancer therapy is not only the largest drug market by a wide margin, but it's also the fastest growing. Specifically, EvaluatePharma expects cancer drug and therapy sales to rise at a compound annual growth of 12.7% over the course of 2016 to 2022. Interestingly enough, the bulk of this growth is forecast to stem from the red-hot area known as immuno-oncology (I-O), or therapies designed to enlist a patient's own immune system in the battle against cancer. I-O offers patients a more targeted tre...
Tags: Finance, Health Care, Agen, Kite, Agenus Inc, Kite Pharma, Getty Images Continue, Kite Pharma NASDAQ, George Budwell, INCY, Agenus Inc NASDAQ, F698cc44-5aee-11e7-8354-0050569d4be0


Pence Hires Outside Counsel To Guide Him Through Russia Investigations

Vice President Mike Pence’s office on Thursday confirmed that Pence has retained outside counsel to guide him through the congressional and federal investigations into Russian interference in the 2016 election. “I can confirm that the Vice President has retained Richard Cullen of McGuire Woods to assist him in responding to inquiries by the special counsel,” Pence’s communications director Jarrod Agen told the Washington Post by email. Agen said Pence “looks forward to a swift conclusion of this...
Tags: News, Washington Post, White House, Russia, Fbi, New York Times, Trump, Mike Pence, Agen, Pence, Mueller, Jarrod Agen, Richard Cullen, Cullen, Robert Mueller, Marc Kasowitz


3 Stocks With Exelixis-Like Return Potential

Over the past year, Exelixis' (NASDAQ: EXEL) stock has more than doubled in value because of the successful commercial launch of advanced kidney cancer drug Cabometyx. Of course, it wasn't that long ago that investors left this high-flying cancer company for dead following this same drug's late-stage miss in advanced prostate cancer. With this compelling turnaround story in mind, we asked three of our contributors which biotech stocks they think might be about to follow in Exelixis' footsteps....
Tags: Finance, Health Care, Agen, Exelixis, Omer, Exel, Getty Images Continue, Brian Feroldi, Exelixis NASDAQ, Omeros Corporation NASDAQ, IMGN, George Budwell Sean Williams, 0f3939ba-42de-11e7-80cd-0050569d4be0


Better Buy: Celldex Therapeutics, Inc. vs. Agenus Inc.

Immuno-oncology (I-O) development is a sizzling-hot area of focus for drug development these days. While many major pharmaceutical companies have either launched or are testing I-O drugs, several clinical-stage biotechs also are developing promising candidates. Celldex Therapeutics (NASDAQ: CLDX) and Agenus (NASDAQ: AGEN) are key players in that group.So far in 2017, however, neither stock has performed very well. Both have fallen around 13% year to date. Over the long run, however, Celldex ...
Tags: Finance, Health Care, Agen, GSK, Agenus Inc, Immuno, CLDX, Getty Images Continue, Celldex Therapeutics Inc, Keith Speights, Celldex, Agenus, 33bbbb2a-3bde-11e7-83b3-0050569d4be0


Here's Why Agenus Inc. Stock Is Climbing Today

Shares of Agenus Inc. (NASDAQ: AGEN) , a clinical-stage biotech developing new cancer therapies, popped on Thursday after providing a handful of updates along with its first-quarter earnings. As of 3:05 p.m. EDT on Thursday, the stock had risen 19.9% higher than the previous day's closing price. Agenus pushed the right buttons with its first-quarter earnings report. The company reported a $124 million cash cushion at the end of March, which was $48 million more than it had at the end of 2016. T...
Tags: Finance, Health Care, Agen, Incyte, Getty Images Continue, 10% Promise, Cory Renauer, Agenus Inc NASDAQ, Db43cb80-30fd-11e7-b894-0050569d4be0


4 Biotech Stocks With Jaw-Dropping Growth Potential

If you're searching for growth stocks with the potential to produce life-changing returns on capital, I think the biotechs Agenus Inc. (NASDAQ: AGEN) , Amarin Corp. (NASDAQ: AMRN) , Cara Therapeutics (NASDAQ: CARA) , and Geron Corp. (NASDAQ: GERN)  are all highly promising.Besides benefiting from the growing and aging global population that's already driving a hefty surge in demand for healthcare services in general, each of these biotechs sports a unique product -- or product candidate -- t...
Tags: Finance, Health Care, Agen, Cara, George Budwell, JNJ, GERN, AMRN, Agenus Inc NASDAQ, Geron Corp NASDAQ, 5d1cfb8a-fe41-11e6-b794-0050569d4be0, AGEN Amarin Corp


Better Buy: Agenus Inc. vs. Celldex Therapeutics

Agenus Inc (NASDAQ: AGEN) and Celldex Therapeutics, Inc. (NASDAQ: CLDX) bear an uncanny resemblance to each other. Both clinical-stage biotechs are focused on developing novel cancer therapies and reported clinical-trial failures with vaccine candidates in development for the treatment of brain cancer.If strikingly similar trial failures weren't freaky enough, the two companies' market values are nearly identical -- right around $350 million. But, when you dig in, the two companies have some...
Tags: Finance, Health Care, Agen, Agenus Inc, CLDX, Celldex Therapeutics, Celldex Therapeutics Inc, Cory Renauer, 62775382-fdce-11e6-bf1f-0050569d4be0


Troubling Trial Data Weighed on Agenus Inc Stock Today

Shares of Agenus Inc (NASDAQ: AGEN) , a biopharmaceutical company developing cancer therapies, had fallen about 14.5% as of 3:20 p.m. EST on Wednesday. Investors weren't too thrilled about its cancer vaccine's recent clinical trial failure.The Prophage G-200 vaccine involved using a patient's own cancer cells to direct a prolonged immune response against their brain tumors. Glioblastoma multiforme is a notoriously difficult-to-treat form of brain cancer, and earlier results suggested adding it ...
Tags: Finance, Health Care, Agen, GSK, Glioblastoma Multiforme, 10% Promise, Cory Renauer, INCY, D507ebe6-f93c-11e6-8aee-0050569d32b9, Agenus Inc Stock Today, Agenus Inc NASDAQ